Administration : Swallow with up to 120 mL (4 oz) plain water on an empty stomach in the morning
Trends in Biochemical Sciences, 49 (11), 969985
Dosing schedule Protocol detail Overview at a glance How it works SLU-PP-332 functions as a synthetic small-molecule pan-agonist for estrogen-related receptors (ERR, ERR, and ERR), showing particular strength at ERR
You cannot access trevogrumab as an approved therapy because the FDA has not authorized it
The primary endpoint is a renal composite episode defined by a decrease in GFR 50%, end-stage renal failure, and death from a renal-cause or cardiovascular-caused death, and it is scheduled for completion in 2024
It can cause nausea and vomiting, especially in the early weeks or during dose increases